Table 1. Baseline characteristics, pulmonary function parameters, stages of COPD, and arterial blood gas analysis results in patients with acute exacerbations and healthy control subjects.
| Variable | AECOPD group | Control group | p |
|---|---|---|---|
| (n = 45) | (n = 20) | ||
| Age (years), mean ± SD | 56.65 ± 6.48 | 57.711 ± 5.723 | 0.510 |
| Male gender, n (%) | 13 (65.0) | 31 (68.9) | 0.758 |
| Current smoker, n (%) | 14 (70.0) | 32 (71.1) | 0.928 |
| Smoking history (pack-years), mean ± SD | 31.00 ± 6.15 | 39.62 ± 9.56 | 0.003 |
| FEV1 (% of predicted), mean ± SD | 87 ± 4.078 | 50.44 ± 19.83 | < 0.001 |
| FEV1/FVC ratio (% of predicted), mean ± SD | 88.2 ± 8.16 | 54.53 ± 10.43 | < 0.001 |
| pH, mean ± SD | 7.38 ± 0.016 | 7.332 ± 0.043 | < 0.001 |
| PaO2 (mmHg), mean ± SD | 75.75 ± 5.18 | 58.77 ± 4.96 | < 0.001 |
| PaCO2 (mmHg), mean ± SD | 41.8 ± 3.17 | 55.40 ± 6.62 | < 0.001 |
| SpO2, mean ± SD | 95.75 ± 1.65 | 88.02 ± 4.25 | < 0.001 |
| GOLD stage of COPD, n (%) | |||
| I | 7 (15.5) | ||
| II | 16 (35.6) | ||
| III | 13 (28.9) | ||
| IV | 9 (20.0) |
AECOPD: acute exacerbation of COPD; and GOLD: Global Initiative for Chronic Obstructive Lung Disease.